The clinical outcomes in patients with ovarian cancer have been significantly improved by Poly(adenosine diphosphate–ribose) polymerase inhibitors (PARP-is). However, the best therapeutic strategy for recurrence during PARP-i maintenance therapy remains unknown. Herein, we elucidated the efficacy of platinum-based chemotherapy after PARP-i treatment in recurrent ovarian cancer. Eligible patients had experienced relapses during PARP-i maintenance therapy lasting at least 6 months and had received subsequent platinum-based chemotherapy at our institution between January 2019 and March 2024. Progression-free survival (PFS), overall survival (OS), and risk factors for PFS were evaluated. Sixty-six patients were assessed for eligibility and eighteen were enrolled. The median follow-up period was 14.5 months. The PFS and OS of all patients were 6.5 and 17.6 months, respectively. The evaluation of the risk factors for PFS revealed that age, pathological type, duration of PARP-i maintenance therapy, prior lines of chemotherapy, and PARP-i dose reduction were not significant prognostic markers. However, bevacizumab use in subsequent therapies significantly extended the PFS. The median PFS was 3.1 months in the chemotherapy-alone group and 8.9 months in the chemotherapy with bevacizumab group (log-rankp= 0.022). Platinum-based chemotherapy with bevacizumab in subsequent therapies would provide substantial benefits in the PFS of patients with recurrent ovarian cancer.
聚腺苷二磷酸核糖聚合酶抑制剂（PARP抑制剂）显著改善了卵巢癌患者的临床预后。然而，对于PARP抑制剂维持治疗期间复发的最佳治疗策略仍不明确。本研究旨在阐明PARP抑制剂治疗后复发性卵巢癌患者接受铂类化疗的疗效。研究纳入2019年1月至2024年3月期间在本机构接受治疗、在持续至少6个月的PARP抑制剂维持治疗期间复发、并后续接受铂类化疗的合格患者。评估指标包括无进展生存期（PFS）、总生存期（OS）以及影响PFS的风险因素。共66例患者接受资格评估，最终18例入组。中位随访时间为14.5个月。所有患者的中位PFS和OS分别为6.5个月和17.6个月。对PFS风险因素的分析显示，年龄、病理类型、PARP抑制剂维持治疗时长、既往化疗线数及PARP抑制剂减量均非显著预后标志。然而，后续治疗中联合使用贝伐珠单抗可显著延长PFS：单纯化疗组中位PFS为3.1个月，而化疗联合贝伐珠单抗组达8.9个月（时序检验p=0.022）。研究结果表明，在后续治疗中采用铂类化疗联合贝伐珠单抗方案，可为复发性卵巢癌患者的无进展生存期带来显著获益。
肿瘤(癌症)患者之家